[1]
“3D MOLECULAR DOCKING COMBINED WITH AI-DRIVEN VIRTUAL SCREENING TO REPURPOSE FDA-APPROVED DRUGS FOR RARE NEURODEGENERATIVE DISEASES”, Int. J. Exp. Biol., vol. 2, no. 01, pp. 50–73, Jun. 2024, Accessed: Nov. 20, 2026. [Online]. Available: https://www.ijeb.online/index.php/IJEB/article/view/23